Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: Paul Senior who wrote (4529)	8/26/2017 11:01:33 AM
From: richardred	Read Replies (2) \| Respond to of 7242

>Stocks of generic drug companies have not been good to me I agree it's been tough on generics. I think its a whole new ballgame out there now. Mylan & Shkreli (Turing Pharma) seem to have started a much publicized downward spiral for many in the group. However insurance companies IMO made it much more a competitive business. That's good for consumers and not stockholders unless you have a competitive advantage. Mylan to Settle EpiPen Overpricing Case for $465 Million P.S. My interest in the company now. I'm speculating ACET will attract a private equity firm wanting to break it up. Generics/mainstays chemicals business. The company mortgaged it self with the latest acquisition. Not only that, it might have more payments to come if the acquisition reaches targets. FWIW my leap calls options were exercised later in the day Friday as the spiral continued. The company's market cap is now trading below the last acquisition. Aceto to pay up to $462M for products, assets of two companies Updated November 2, 2016 7:11 PM newsday.com >Citron and Lucid together are expected to generate $40 million of adjusted EBITDA on revenue of $195 million Dec 2010 Aceto Corp. To Buy Rising Pharmaceuticals For $80 Millionhttp://www.proactiveinvestors.com/companies/news/75404/aceto-corp-to-buy-rising-pharmaceuticals-for-80-million-10905.html snip>Rising is expected to earn about $49 million of revenues for 2010. Poor outlook-For fiscal 2018, the company expects revenues to increase 20% to 25% and non-GAAP EPS to increase to between $1.25 and $1.40, compared with market consensus of $1.77 for EPS